Sensei Biotherapeutics (NASDAQ:FTH) Earns Buy Rating from HC Wainwright

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $60.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 110.01% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the company. Citigroup began coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price for the company. Raymond James Financial began coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 price objective on the stock. Oppenheimer assumed coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price on the stock. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Finally, Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They set an “outperform” rating and a $57.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $54.90.

Sensei Biotherapeutics Stock Up 17.1%

FTH opened at $28.57 on Tuesday. Sensei Biotherapeutics has a 52-week low of $7.21 and a 52-week high of $37.90. The company has a market cap of $38.28 million, a price-to-earnings ratio of -0.20 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, research analysts predict that Sensei Biotherapeutics will post -13.18 earnings per share for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 25,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the transaction, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This trade represents a 16.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was purchased at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the purchase, the chief financial officer directly owned 46,688 shares of the company’s stock, valued at approximately $1,097,168. This represents a 11.99% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 49,494 shares of company stock valued at $1,188,822. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its position in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after acquiring an additional 1,100 shares in the last quarter. Bank of America Corp DE increased its stake in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Stempoint Capital LP bought a new position in Sensei Biotherapeutics in the first quarter worth about $4,188,000. Finally, Vivo Capital LLC bought a new position in Sensei Biotherapeutics in the first quarter worth about $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.